항균제 감수성 시험(AST) : 시장 동향, 경쟁 구도, 시장 예측(-2034년)

Antimicrobial Susceptibility Testing Market Summary

• The global antimicrobial susceptibility testing market is expected to increase from USD 4,128.15 million in 2025 to USD 6,475.48 million by 2034, reflecting strong and sustained growth.
• The global antimicrobial susceptibility testing market is growing at a CAGR of 5.18% during the forecast period from 2026 to 2034.
• The rising burden of infectious diseases, including conditions such as Sepsis and Urinary Tract Infections, is increasing the need for accurate diagnosis and effective treatment selection, thereby driving demand for antimicrobial susceptibility testing (AST). At the same time, the growing emphasis on targeted and personalized therapy is shifting clinical practice away from empirical antibiotic use toward evidence-based treatment, where AST plays a crucial role in identifying the most effective drug for each patient. This demand is further strengthened by technological advancements in AST systems, such as automation and rapid testing platforms, which significantly reduce turnaround time and improve diagnostic accuracy. Collectively, these factors are accelerating the adoption of AST across healthcare settings, thereby boosting the overall market growth.
• The leading companies operating in the antimicrobial susceptibility testing market include bioMerieux SA, Becton, Dickinson and Company (BD), Thermo Fisher Scientific Inc., Beckman Coulter, Inc., Danaher Corporation, Bio-Rad Laboratories, Inc., Bruker Corporation, Accelerate Diagnostics, Inc., Luminex Corporation, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, HiMedia Laboratories Pvt. Ltd., Hardy Diagnostics, Liofilchem S.r.l., Merck KGaA, Charles River Laboratories International, Inc., QIAGEN N.V., Cepheid, Inc., and others.
• North America is expected to dominate the antimicrobial susceptibility testing market due to the high prevalence of infectious diseases and antimicrobial resistance, advanced healthcare infrastructure, and strong presence of leading diagnostic companies. Additionally, widespread adoption of automated and rapid diagnostic technologies, along with supportive initiatives by organizations such as the Centers for Disease Control and Prevention and Food and Drug Administration to combat antimicrobial resistance, further drives the demand for AST solutions across the region.
• In the product segment of the antimicrobial susceptibility testing market, the manual testing category is estimated to account for the largest market share in 2025.

Factors Contributing to the Growth of the Antimicrobial Susceptibility Testing Market

• Rising burden of infectious disease leading to a surge in antimicrobial susceptibility testing: The rising burden of infectious diseases, including conditions such as sepsis, tuberculosis, and urinary tract infections, is significantly boosting the demand for antimicrobial susceptibility testing. As infection rates increase, there is a greater need for accurate and timely identification of effective antimicrobial therapies. AST helps clinicians determine the most appropriate treatment, reduce trial-and-error prescribing, and improve patient outcomes. This growing reliance on precise diagnostics is driving the adoption of AST across hospitals, laboratories, and healthcare systems, thereby supporting overall market growth.
• Growing demand for targeted & personalized therapy: The growing demand for targeted and personalized therapy is significantly boosting the antimicrobial susceptibility testing (AST) market, as healthcare providers increasingly move away from empirical antibiotic use toward precision-based treatment. AST enables clinicians to identify the most effective antimicrobial for a specific pathogen, ensuring optimized therapy for conditions such as Sepsis and Urinary Tract Infections. This approach not only improves patient outcomes but also helps minimize unnecessary antibiotic use and combat resistance. As a result, the increasing focus on personalized medicine is driving greater adoption of AST solutions across clinical settings.
• Technological advancements in AST systems: Technological advancements in antimicrobial susceptibility testing (AST) systems are significantly boosting the market by improving the speed, accuracy, and efficiency of diagnostics. The development of automated platforms and rapid AST technologies enables faster detection of effective treatments for infections such as Sepsis and Tuberculosis, reducing turnaround time from days to hours. Additionally, innovations like digital microbiology, AI integration, and high-throughput systems enhance workflow efficiency and reduce human error. These improvements are encouraging healthcare facilities to adopt advanced AST solutions, thereby driving overall market growth.

Antimicrobial Susceptibility Testing Market Report Segmentation

This antimicrobial susceptibility testing market report offers a comprehensive overview of the global antimicrobial susceptibility testing market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product (Automated Instruments and Manual Testing), Organism Type (Bacteria, Fungi, and Parasites), Method Type (Phenotypic {Disk Diffusion (Kirby-Bauer method), Broth Dilution (MIC testing), E-test (gradient diffusion), and Agar Dilution} and Genotypic { PCR-based, DNA Sequencing, Microarray-based}), Application (Clinical Diagnostics, Drug Discovery & Development, Epidemiology & Surveillance, and Others), End-Users (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Others) and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing Antimicrobial Susceptibility Testing market.

Antimicrobial Susceptibility Testing (AST) is a laboratory process used to determine how sensitive a microorganism, such as bacteria or fungi, is to specific antimicrobial drugs. It helps identify the most effective treatment by evaluating whether a pathogen is inhibited or resistant to antibiotics, which is especially critical in managing infections like Sepsis and Tuberculosis. This enables clinicians to select appropriate therapy, improve patient outcomes, and reduce the risk of antimicrobial resistance.

The rising burden of infectious diseases, including conditions such as Sepsis and Urinary Tract Infections, is significantly increasing the need for accurate diagnosis and effective treatment selection, thereby driving demand for antimicrobial susceptibility testing (AST). As infection rates continue to grow globally, healthcare providers are under greater pressure to ensure timely and precise identification of the most effective antimicrobial therapy, reducing complications, hospital stays, and mortality rates. At the same time, the growing emphasis on targeted and personalized therapy is shifting clinical practice away from empirical antibiotic use toward evidence-based treatment approaches. In this context, AST plays a crucial role by enabling clinicians to tailor therapies based on the specific resistance profile of pathogens, improving patient outcomes while minimizing unnecessary antibiotic exposure.

This demand is further strengthened by continuous technological advancements in AST systems, including automation, rapid diagnostic platforms, and integration with digital laboratory workflows. These innovations significantly reduce turnaround time from days to hours while enhancing accuracy, reproducibility, and laboratory efficiency. Additionally, the incorporation of advanced data analytics and streamlined workflows is supporting faster clinical decision-making. Collectively, these factors are accelerating the adoption of AST across hospitals, diagnostic laboratories, and research settings, thereby driving sustained growth in the overall market.

What are the latest antimicrobial susceptibility testing market dynamics and trends?

The rising burden of infectious diseases such as sepsis, tuberculosis, hospital-acquired infections (HAIs), gastrointestinal infections, and urinary tract infections worldwide is significantly boosting the overall market of antimicrobial susceptibility testing.

According to the World Sepsis Day Organization (2025), around 47 to 50 million cases of sepsis occur each year across the world. Sepsis progresses quickly and is often associated with high mortality if not treated promptly with the right antibiotics. This creates a strong demand for AST to determine the most appropriate drug based on the pathogen's susceptibility profile, reducing the reliance on broad-spectrum antibiotics and minimizing treatment failure.

Additionally, according to the World Health Organization (2026), in 2024, an estimated 10.7 million people fell ill with TB worldwide. Effective treatment of tuberculosis requires precise identification of antibiotic resistance patterns, as standard therapies may fail in resistant cases. AST plays a critical role in determining the most appropriate drug regimen, reducing treatment failures, and improving patient outcomes.

Furthermore, according to the facts provided by the World Health Organization (2025), on average, around 1 in 10 patients was affected by hospital-acquired infections. Common HAIs such as ventilator-associated pneumonia, bloodstream infections, and surgical site infections increase the need for accurate identification of effective antibiotics. AST enables clinicians to determine the most appropriate therapy, reduce the misuse of broad-spectrum antibiotics, and improve patient outcomes.

Additionally, the growing demand for targeted and personalized therapy is significantly boosting the antimicrobial susceptibility testing (AST) market, as healthcare systems increasingly prioritize precision-based treatment over empirical antibiotic use. AST plays a critical role in identifying the most effective antimicrobial for a specific pathogen, enabling clinicians to tailor therapies based on individual patient needs and resistance profiles. This approach not only improves clinical outcomes but also reduces the misuse of broad-spectrum antibiotics and helps combat antimicrobial resistance. As precision medicine continues to gain traction globally, the reliance on accurate and rapid AST solutions is increasing across hospitals and diagnostic laboratories, thereby driving overall market growth. In addition to this demand, several recent development activities are further accelerating the AST market. For instance, in February 2024, the U.S. Food and Drug Administration cleared the Selux AST System, an advanced automated platform capable of testing multiple antibiotics simultaneously and delivering faster results compared to traditional methods.

Collectively, the shift toward personalized therapy, combined with continuous product innovations, increasing burden of infectious diseases, and regulatory approvals, is accelerating the adoption of advanced AST systems and driving sustained growth in the global market.

However, the long turnaround times, challenges in testing fastidious and rare organisms, and stringent regulatory approval processes are key factors limiting the growth of the antimicrobial susceptibility testing (AST) market. Traditional AST methods often require extended incubation periods, delaying clinical decision-making and reducing efficiency. Additionally, certain difficult-to-culture pathogens complicate accurate susceptibility testing, leading to gaps in diagnosis and treatment. Furthermore, strict regulatory requirements for product approvals increase development timelines and costs for manufacturers, slowing the introduction of innovative AST technologies. Collectively, these factors hinder widespread adoption and act as restraints on overall market growth.

Antimicrobial Susceptibility Testing Market Segment Analysis

Antimicrobial Susceptibility Testing Market by Product (Automated Instruments and Manual Testing), Organism Type (Bacteria, Fungi, and Parasites), Method Type (Phenotypic {Disk Diffusion (Kirby-Bauer method), Broth Dilution (MIC testing), E-test (gradient diffusion), and Agar Dilution} and Genotypic {PCR-based, DNA Sequencing, Microarray-based}), Application (Clinical Diagnostics, Drug Discovery & Development, Epidemiology & Surveillance, and Others), End-Users (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Antimicrobial Susceptibility Testing Market Regional Analysis

North America Antimicrobial Susceptibility Testing Market Trends

North America is expected to account for the highest proportion of 44.67% of the antimicrobial susceptibility testing market in 2025, out of all regions. North America is expected to dominate the Antimicrobial Susceptibility Testing market due to the high prevalence of infectious diseases and antimicrobial resistance, advanced healthcare infrastructure, and strong presence of leading diagnostic companies. Additionally, widespread adoption of automated and rapid diagnostic technologies, along with supportive initiatives by organizations such as the Centers for Disease Control and Prevention and Food and Drug Administration to combat antimicrobial resistance, further drives the demand for AST solutions across the region.

According to the data provided by the Centre for Disease Control and Prevention (2026), each year, at least 1.7 million adults and more than 18,000 children in the U.S. develop sepsis.

Additionally, as per the same source, in 2023, the United States reported 9,633 cases of tuberculosis disease. Tuberculosis (TB) and sepsis are significantly boosting the antimicrobial susceptibility testing (AST) market due to the urgent need for accurate and timely antibiotic sensitivity data to guide effective treatment. In TB, the rise of multidrug-resistant and extensively drug-resistant strains has made susceptibility testing essential for selecting appropriate drug regimens and supporting global TB control programs. In sepsis, which is a life-threatening bloodstream infection, rapid AST is critical for identifying the causative bacteria and ensuring immediate administration of effective antibiotics, especially in intensive care settings. The increasing prevalence of resistant infections in both conditions is driving higher demand for AST instruments, reagents, and consumables, thereby supporting overall market growth.

However, the increase in product development activities among the key market players is further boosting the overall market. For instance, in April 2025, Becton, Dickinson and Company received U.S. FDA clearance for updated BD Phoenix(TM) M50 and M100 systems panels, which include enhanced bacterial identification and susceptibility testing capabilities, supporting faster and more standardized bacterial AST workflows.

Collectively, these factors are expected to significantly drive the growth of the antimicrobial susceptibility testing market in North America throughout the forecast period of 2026 to 2034.

Europe Antimicrobial Susceptibility Testing Market Trends

The antimicrobial susceptibility testing market in Europe is witnessing strong and sustained growth due to the rising burden of infectious diseases. According to the data provided by the European Centre for Disease Prevention and Control (2025), an estimated 204,000 people fell ill with tuberculosis (TB) in 2024 in Europe. Additionally, Europe is witnessing strong and sustained growth due to the region's high focus on antimicrobial resistance (AMR) control, well-established clinical microbiology infrastructure, and strict standardization of testing practices. A key growth driver is the widespread implementation of harmonized AST guidelines under the European Committee on Antimicrobial Susceptibility Testing, which standardizes breakpoints and interpretation criteria across European laboratories, ensuring consistent and high-quality susceptibility reporting across countries.

The market is further strengthened by ongoing technological advancements and EU-regulated product launches and system upgrades from leading diagnostic companies. For example, in June 2023, Sysmex Europe GmbH launched a point-of-care antimicrobial susceptibility testing system in Europe capable of delivering AST results in approximately 30 minutes directly from urine samples, significantly reducing turnaround time compared to conventional culture-based methods.

Thus, the factors mentioned above are expected to boost the overall market of antimicrobial susceptibility in Europe.

Asia-Pacific Antimicrobial Susceptibility Testing Market Trends

The Asia Pacific (APAC) region is emerging as a major growth driver for the Antimicrobial Susceptibility Testing market due to its large patient population, rapidly increasing burden of infectious diseases, and rising antimicrobial resistance (AMR) across key countries such as China, India, and Japan. The region is witnessing a sharp rise in hospital-acquired infections and multidrug-resistant bacterial strains, which is significantly increasing the demand for accurate and timely susceptibility testing to guide effective antibiotic therapy. At the same time, governments across APAC are heavily investing in healthcare infrastructure, expanding diagnostic laboratory networks, and implementing national AMR action plans, which are accelerating the adoption of both automated and manual AST systems in hospitals and reference laboratories. The growing awareness among clinicians about antimicrobial stewardship, along with increasing access to advanced diagnostic technologies such as rapid AST platforms and automated systems, is further strengthening market penetration. Additionally, countries like India and China are scaling up large surveillance programs for resistance monitoring, which requires continuous and high-volume AST testing. Combined with improving affordability of diagnostic solutions and expansion of private healthcare facilities, these factors are positioning APAC as the fastest-growing and most dynamic region in the global AST market, with strong long-term growth potential driven by rising infection rates and expanding diagnostic capabilities.

Who are the major players in the antimicrobial susceptibility testing market?

The following are the leading companies in the antimicrobial susceptibility testing market. These companies collectively hold the largest market share and dictate industry trends.

• bioMerieux SA
• Becton, Dickinson and Company (BD)
• Thermo Fisher Scientific Inc.
• Beckman Coulter, Inc.
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• Bruker Corporation
• Accelerate Diagnostics, Inc.
• Luminex Corporation
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• HiMedia Laboratories Pvt. Ltd.
• Hardy Diagnostics
• Liofilchem S.r.l.
• Merck KGaA
• Charles River Laboratories International, Inc.
• QIAGEN N.V.
• Cepheid, Inc.
• Others

How is the competitive landscape shaping the antimicrobial susceptibility testing market?

The competitive landscape of the antimicrobial susceptibility testing (AST) market is highly dynamic and moderately consolidated, with a few global diagnostic leaders dominating alongside several regional and niche players. Major companies such as Becton, Dickinson and Company, bioMerieux, Thermo Fisher Scientific, and Danaher (through subsidiaries like Beckman Coulter) hold strong positions due to their broad portfolios of automated AST systems, consumables, and integrated laboratory solutions. Competition is increasingly shaped by continuous innovation in rapid and automated testing platforms, integration with laboratory information systems, and expansion of antimicrobial resistance (AMR) testing capabilities. Companies are actively investing in R&D to reduce turnaround time, improve accuracy, and enable real-time or same-day susceptibility reporting, which is becoming a key differentiator in hospital and high-throughput laboratory settings. Strategic collaborations, partnerships with hospitals and research institutions, and mergers and acquisitions are also common strategies used to expand geographic reach and strengthen product pipelines. For example, industry players are increasingly combining diagnostics with digital and AI-driven data interpretation tools to support antimicrobial stewardship programs and clinical decision-making. At the same time, emerging companies are introducing rapid point-of-care AST solutions, increasing competitive pressure and pushing established firms to accelerate innovation cycles. Overall, the competitive landscape is being reshaped by automation, rapid diagnostics, and integrated digital ecosystems, making AST solutions more efficient, scalable, and clinically impactful in the fight against antimicrobial resistance.

Recent Developmental Activities in the Antimicrobial Susceptibility Testing Market

• In January 2026, emerging companies secured significant funding to develop next-generation rapid AST solutions capable of delivering results within one hour, reflecting strong industry momentum toward faster and more precise diagnostics.
• In April 2025, Becton, Dickinson and Company received U.S. FDA clearance for updated BD Phoenix(TM) M50 and M100 systems panels, which include enhanced bacterial identification and susceptibility testing capabilities, supporting faster and more standardized bacterial AST workflows.

Antimicrobial Susceptibility Testing Market Segmentation

• Antimicrobial Susceptibility Testing by Product Exposure
• Automated Instruments
• Manual Testing
• Antimicrobial Susceptibility Testing Organism Type Exposure
• Bacteria
• Fungi
• Parasites
• Antimicrobial Susceptibility Testing Method Type Exposure
• Phenotypic
• Disk Diffusion (Kirby-Bauer method)
• Broth Dilution (MIC testing)
• E-test (gradient diffusion), and Agar Dilution
• Genotypic
• PCR-based
• DNA Sequencing
• Microarray-based
• Antimicrobial Susceptibility Testing Application Exposure
• Clinical Diagnostics
• Drug Discovery & Development
• Epidemiology & Surveillance
• Others
• Antimicrobial Susceptibility Testing End-Users Exposure
• Hospitals & Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others
• Antimicrobial Susceptibility Testing Geography Exposure
• North America Antimicrobial Susceptibility Testing Market
• United States Antimicrobial Susceptibility Testing Market
• Canada Antimicrobial Susceptibility Testing Market
• Mexico Antimicrobial Susceptibility Testing Market
• Europe Antimicrobial Susceptibility Testing Market
• United Kingdom Antimicrobial Susceptibility Testing Market
• Germany Antimicrobial Susceptibility Testing Market
• France Antimicrobial Susceptibility Testing Market
• Italy Antimicrobial Susceptibility Testing Market
• Spain Antimicrobial Susceptibility Testing Market
• Rest of Europe Antimicrobial Susceptibility Testing Market
• Asia-Pacific Antimicrobial Susceptibility Testing Market
• China Antimicrobial Susceptibility Testing Market
• Japan Antimicrobial Susceptibility Testing Market
• India Antimicrobial Susceptibility Testing Market
• Australia Antimicrobial Susceptibility Testing Market
• South Korea Antimicrobial Susceptibility Testing Market
• Rest of Asia-Pacific Antimicrobial Susceptibility Testing Market
• Rest of the World Antimicrobial Susceptibility Testing Market
• South America Antimicrobial Susceptibility Testing Market
• Middle East Antimicrobial Susceptibility Testing Market
• Africa Antimicrobial Susceptibility Testing Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations in the antimicrobial susceptibility testing (AST) market are transforming how laboratories detect, interpret, and report antimicrobial resistance by making testing faster, more accurate, and highly standardized. Artificial intelligence and machine learning algorithms are increasingly being integrated into AST platforms to analyze bacterial growth patterns, inhibition zones, and time-lapse imaging data to predict susceptibility results earlier than conventional methods. These systems can identify subtle phenotypic changes in microbial growth and correlate them with resistance profiles, helping reduce turnaround time and support faster clinical decision-making, especially in critical infections like sepsis. AI is also being used to improve breakpoint interpretation and result standardization, minimizing inter-laboratory variability and ensuring consistency with evolving guidelines from bodies such as CLSI and EUCAST. In addition, AI-driven AST platforms enable predictive resistance modeling, where historical and real-time microbiology data are analyzed to forecast likely resistance patterns, supporting antimicrobial stewardship programs and empirical therapy selection. Integration of AI with automated AST instruments and digital microbiology systems allows real-time data processing, remote monitoring, and cloud-based reporting, improving laboratory efficiency and workflow optimization. Overall, AI is shifting AST from a purely manual, time-dependent process to an intelligent, data-driven ecosystem that enhances speed, accuracy, and clinical utility in combating antimicrobial resistance.

U.S. Tariff Impact Analysis on Antimicrobial Susceptibility Testing Market:

The U.S. tariff impact analysis on the antimicrobial susceptibility testing (AST) market indicates that tariffs primarily affect the cost structure, supply chain efficiency, and pricing of instruments, reagents, and consumables rather than demand for AST itself. Since AST relies heavily on globally sourced components such as antibiotic disks, culture media, diagnostic reagents, and automated instrument parts import tariffs can increase landed costs for manufacturers like Thermo Fisher Scientific, bioMerieux, and Becton, Dickinson and Company when importing raw materials or finished consumables into the U.S. This leads to higher production costs, which may be partially passed on to hospitals and diagnostic laboratories in the form of increased pricing for AST kits and systems. Additionally, tariffs can create supply chain disruptions and sourcing delays, particularly for specialized consumables like antibiotic susceptibility disks and MIC panels that are often manufactured or assembled in multiple regions. However, the impact is somewhat moderated because the AST market is medically essential and non-discretionary, meaning demand remains stable even if costs rise. As a result, companies often respond by shifting manufacturing closer to the U.S., diversifying suppliers, or expanding domestic production capabilities to reduce tariff exposure. Overall, tariffs tend to increase operational costs and encourage localization of manufacturing, but they do not significantly reduce AST adoption due to the critical role of susceptibility testing in managing antimicrobial resistance and guiding clinical treatment decisions.

How This Analysis Helps Clients

• Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
• Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
• Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
• Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the Antimicrobial Susceptibility Testing market report study

• Market size analysis for the current antimicrobial susceptibility testing market size (2025), and market forecast for 8 years (2026 to 2034)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the antimicrobial susceptibility testing market.
• Various opportunities available for the other competitors in the antimicrobial susceptibility testing market space.
• What are the top-performing segments in 2025? How these segments will perform in 2034?
• Which are the top-performing regions and countries in the current antimicrobial susceptibility testing market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the antimicrobial susceptibility testing market growth in the future.

Frequently Asked Questions for the Antimicrobial Susceptibility Testing Market

1. What is the growth rate of the antimicrobial susceptibility testing market?

• The antimicrobial susceptibility testing market is estimated to grow at a CAGR of 5.18% during the forecast period from 2026 to 2034.

2. What is the market for antimicrobial susceptibility testing?

• The global antimicrobial susceptibility testing market is expected to increase from USD 4,128.15 million in 2025 to USD 6,475.48 million by 2034.

3. Which region has the highest share in the antimicrobial susceptibility testing market?

• North America is expected to dominate the antimicrobial susceptibility testing market due to the high prevalence of infectious diseases and antimicrobial resistance, advanced healthcare infrastructure, and strong presence of leading diagnostic companies. Additionally, widespread adoption of automated and rapid diagnostic technologies, along with supportive initiatives by organizations such as the Centers for Disease Control and Prevention and Food and Drug Administration to combat antimicrobial resistance, further drives the demand for AST solutions across the region.

4. What are the drivers for the antimicrobial susceptibility testing market?

• The rising burden of infectious diseases, including conditions such as Sepsis and Urinary Tract Infections, is increasing the need for accurate diagnosis and effective treatment selection, thereby driving demand for antimicrobial susceptibility testing (AST). At the same time, the growing emphasis on targeted and personalized therapy is shifting clinical practice away from empirical antibiotic use toward evidence-based treatment, where AST plays a crucial role in identifying the most effective drug for each patient. This demand is further strengthened by technological advancements in AST systems, such as automation and rapid testing platforms, which significantly reduce turnaround time and improve diagnostic accuracy. Collectively, these factors are accelerating the adoption of AST across healthcare settings, thereby boosting the overall market growth.

5. Who are the key players operating in the antimicrobial susceptibility testing market?

• Some of the key market players operating in the antimicrobial susceptibility testing market include bioMerieux SA, Becton, Dickinson and Company (BD), Thermo Fisher Scientific Inc., Beckman Coulter, Inc., Danaher Corporation, Bio-Rad Laboratories, Inc., Bruker Corporation, Accelerate Diagnostics, Inc., Luminex Corporation, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, HiMedia Laboratories Pvt. Ltd., Hardy Diagnostics, Liofilchem S.r.l., Merck KGaA, Charles River Laboratories International, Inc., QIAGEN N.V., Cepheid, Inc., and others.

Table of Contents

1. Antimicrobial Susceptibility Testing Market Report Introduction

• 1.1 Scope of the Study
• 1.2 Market Segmentation
• 1.3 Market Assumption

2. Antimicrobial Susceptibility Testing Market Executive Summary

• 2.1 Market at Glance

3. Antimicrobial Susceptibility Testing Market Key Factors Analysis

• 3.1 Antimicrobial Susceptibility Testing Market Drivers
  • 3.1.1 Rising burden of infectious disease.
  • 3.1.2 Growing demand for targeted & personalized therapy
  • 3.1.3 Technological advancements in AST systems
• 3.2 Antimicrobial Susceptibility Testing Market Restraints and Challenges
  • 3.2.1 Long turnaround time and challenges with fastidious and rare organisms
  • 3.2.2 Stringent regulatory process for product approval
• 3.3 Antimicrobial Susceptibility Testing Market Opportunity
  • 3.3.1 Shift toward rapid and point-of-care AST solutions

4. Impact Analysis

• 4.1 AI-Powered Innovations and Applications
• 4.2 U.S. Tariff Impact Analysis

5. Regulatory Analysis

• 5.1 The United States
• 5.2 Europe
• 5.3 Japan
• 5.4 China

6. Antimicrobial Susceptibility Testing Market Porter's Five Forces Analysis

• 6.1 Bargaining Power of Suppliers
• 6.2 Bargaining Power of Consumers
• 6.3 Threat of New Entrants
• 6.4 Threat of Substitutes
• 6.5 Competitive Rivalry

7. Antimicrobial Susceptibility Testing Market Assessment

• 7.1 By Product
  • 7.1.1 Automated Instruments
  • 7.1.2 Manual Testing
• 7.2 By Organism Type
  • 7.2.1 Bacteria
  • 7.2.2 Fungi
  • 7.2.3 Parasites
• 7.3 By Method Type
  • 7.3.1 Phenotypic
    • 7.3.1.1 Disk Diffusion (Kirby-Bauer method)
    • 7.3.1.2 Broth Dilution (MIC testing)
    • 7.3.1.3 E-test (gradient diffusion)
    • 7.3.1.4 Agar Dilution
  • 7.3.2 Genotypic
    • 7.3.2.1 PCR-based
    • 7.3.2.2 DNA Sequencing
    • 7.3.2.3 Microarray-based
• 7.4 By Application
  • 7.4.1 Clinical Diagnostics
  • 7.4.2 Drug Discovery & Development
  • 7.4.3 Epidemiology & Surveillance
  • 7.4.4 Others
• 7.5 By End-Users
  • 7.5.1 Hospitals & Diagnostic Laboratories
  • 7.5.2 Pharmaceutical & Biotechnology Companies
  • 7.5.3 Academic & Research Institutes
  • 7.5.4 Others
• 7.6 By Geography
  • 7.6.1 North America
    • 7.6.1.1 United States Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.1.2 Canada Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.1.3 Mexico Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • 7.6.2 Europe
    • 7.6.2.1 France Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.2.2 Germany Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.2.3 United Kingdom Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.2.4 Italy Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.2.5 Spain Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.2.6 Rest of Europe Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • 7.6.3 Asia-Pacific
    • 7.6.3.1 China Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.3.2 Japan Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.3.3 India Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.3.4 Australia Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.3.5 South Korea Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.3.6 Rest of Asia-Pacific Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
  • 7.6.4 Rest of the World (RoW)
    • 7.6.4.1 Middle East Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.4.2 Africa Antimicrobial Susceptibility Testing Market Size in USD million (2023-2034)
    • 7.6.4.3 South America Antimicrobial Susceptibility Testing Market Size In USD Million (2023-2034)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Antimicrobial Susceptibility Testing Market Company and Product Profiles

• 10.1 bioMerieux SA
  • 10.1.1 Company Overview
  • 10.1.2 Company Snapshot
  • 10.1.3 Financial Overview
  • 10.1.4 Product Listing
  • 10.1.5 Entropy
• 10.2 Becton, Dickinson and Company (BD)
  • 10.2.1 Company Overview
  • 10.2.2 Company Snapshot
  • 10.2.3 Financial Overview
  • 10.2.4 Product Listing
  • 10.2.5 Entropy
• 10.3 Thermo Fisher Scientific Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Snapshot
  • 10.3.3 Financial Overview
  • 10.3.4 Product Listing
  • 10.3.5 Entropy
• 10.4 Beckman Coulter, Inc.
  • 10.4.1 Company Overview
  • 10.4.2 Company Snapshot
  • 10.4.3 Financial Overview
  • 10.4.4 Product Listing
  • 10.4.5 Entropy
• 10.5 Danaher Corporation
  • 10.5.1 Company Overview
  • 10.5.2 Company Snapshot
  • 10.5.3 Financial Overview
  • 10.5.4 Product Listing
  • 10.5.5 Entropy
• 10.6 Bio-Rad Laboratories, Inc.
  • 10.6.1 Company Overview
  • 10.6.2 Company Snapshot
  • 10.6.3 Financial Overview
  • 10.6.4 Product Listing
  • 10.6.5 Entropy
• 10.7 Bruker Corporation
  • 10.7.1 Company Overview
  • 10.7.2 Company Snapshot
  • 10.7.3 Financial Overview
  • 10.7.4 Product Listing
  • 10.7.5 Entropy
• 10.8 Accelerate Diagnostics, Inc.
  • 10.8.1 Company Overview
  • 10.8.2 Company Snapshot
  • 10.8.3 Financial Overview
  • 10.8.4 Product Listing
  • 10.8.5 Entropy
• 10.9 Luminex Corporation
  • 10.9.1 Company Overview
  • 10.9.2 Company Snapshot
  • 10.9.3 Financial Overview
  • 10.9.4 Product Listing
  • 10.9.5 Entropy
• 10.10 Abbott Laboratories
  • 10.10.1 Company Overview
  • 10.10.2 Company Snapshot
  • 10.10.3 Financial Overview
  • 10.10.4 Product Listing
  • 10.10.5 Entropy
• 10.11 F. Hoffmann-La Roche Ltd.
  • 10.11.1 Company Overview
  • 10.11.2 Company Snapshot
  • 10.11.3 Financial Overview
  • 10.11.4 Product Listing
  • 10.11.5 Entropy
• 10.12 Siemens Healthineers AG
  • 10.12.1 Company Overview
  • 10.12.2 Company Snapshot
  • 10.12.3 Financial Overview
  • 10.12.4 Product Listing
  • 10.12.5 Entropy
• 10.13 HiMedia Laboratories Pvt. Ltd.
  • 10.13.1 Company Overview
  • 10.13.2 Company Snapshot
  • 10.13.3 Financial Overview
  • 10.13.4 Product Listing
  • 10.13.5 Entrophy
• 10.14 Hardy Diagnostics
  • 10.14.1 Company Overview
  • 10.14.2 Company Snapshot
  • 10.14.3 Financial Overview
  • 10.14.4 Product Listing
  • 10.14.5 Entrophy
• 10.15 Liofilchem S.r.l.
  • 10.15.1 Company Overview
  • 10.15.2 Company Snapshot
  • 10.15.3 Financial Overview
  • 10.15.4 Product Listing
  • 10.15.5 Entrophy
• 10.16 Merck KGaA
  • 10.16.1 Company Overview
  • 10.16.2 Company Snapshot
  • 10.16.3 Financial Overview
  • 10.16.4 Product Listing
  • 10.16.5 Entrophy
• 10.17 Charles River Laboratories International, Inc.
  • 10.17.1 Company Overview
  • 10.17.2 Company Snapshot
  • 10.17.3 Financial Overview
  • 10.17.4 Product Listing
  • 10.17.5 Entrophy
• 10.18 QIAGEN N.V.
  • 10.18.1 Company Overview
  • 10.18.2 Company Snapshot
  • 10.18.3 Financial Overview
  • 10.18.4 Product Listing
  • 10.18.5 Entrophy
• 10.19 Cepheid, Inc.
  • 10.19.1 Company Overview
  • 10.19.2 Company Snapshot
  • 10.19.3 Financial Overview
  • 10.19.4 Product Listing
  • 10.19.5 Entrophy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us